Entrada Therapeutics Inc
TRDA
查看详细走势图
11.930USD
-0.380-3.09%
收盘 03/27, 16:00（美东）报价延迟15分钟
448.26M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.09%
5天
+5.48%
1月
0.00%
6月
+105.69%
今年开始到现在
+16.05%
1年
+24.79%
查看详细走势图
TradingKey Entrada Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Entrada Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名63/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价20.00。中期看，股价处于上升通道。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Entrada Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Entrada Therapeutics Inc亮点
亮点风险
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
业绩增长期
公司处于发展阶段，最新年度总收入25.42M美元
利润高增长
公司净利润处于行业前列，最新年度总收入25.42M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值合理
公司最新PE估值-3.43，处于3年历史合理位
机构减仓
最新机构持股29.95M股，环比减少3.97%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值30.63K
活跃度增加
近期活跃度增加，过去20天平均换手率1.05
分析师目标
根据
7
位分析师
买入
评级
20.000
目标均价
+62.47%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Entrada Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Entrada Therapeutics Inc简介
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
公司代码TRDA
公司Entrada Therapeutics Inc
CEODoshi (Dipal)
网址https://www.entradatx.com/
相关品种
